Top
Summary
All studies
Mortality
Serious outcomes
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All darunavir studies
..
Feedback
Home
c19early.org COVID-19 treatment researchDarunavirDarunavir (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 darunavir studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Serious outcomes   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -34% 5 2,976 Improvement, Studies, Patients Relative Risk Mortality -34% 4 2,946 Viral clearance -22% 1 30 RCTs -22% 1 30 Early -22% 1 30 Late -34% 4 2,946 Darunavir for COVID-19 c19early.org May 2025 Favorsdarunavir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.82-2.20] 2/774 14/2,202 34% higher risk 5 darunavir COVID-19 studies c19early.org May 2025 Tau​2​ = 0.22, I​2​ = 79.7%, p = 0.24 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Nicolini -32% 1.32 [0.85-2.06] 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] 2/14 14/28 Milic -150% 2.50 [1.58-3.94] 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk 4 darunavir COVID-19 mortality results c19early.org May 2025 Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk 4 darunavir COVID-19 serious outcomes c19early.org May 2025 Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk All studies -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk 1 darunavir COVID-19 viral clearance result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk All studies -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk 1 darunavir COVID-19 Randomized Controlled Trial c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.82-2.20] 2/774 14/2,202 34% higher risk 5 darunavir COVID-19 peer reviewed studies c19early.org May 2025 Tau​2​ = 0.22, I​2​ = 79.7%, p = 0.24 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) Milic -48% 1.48 [1.04-2.11] death/int. 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Darunavir COVID-19 outcomes c19early.org May 2025 Favors darunavir Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0